Irbesartan/Hydrochloorthiazide Stada

Irbesartan, the active ingredient in Irbesartan/Hydrochloorthiazide Stada, is an Angiotensin II receptor blocker (ARB) presented as a fixed‑dose oral tablet for oral use. It treats hypertension in adult patients by lowering elevated blood pressure.

GNH USA supplies Irbesartan/Hydrochloorthiazide Stada as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Irbesartan/Hydrochlorothiazide is used in the management of hypertension, a condition characterized by chronically elevated arterial pressure. - Hypertension: reduces systolic and diastolic blood pressure, helping to prevent cardiovascular complications. - Essential hypertension: provides combined ARB and thiazide diuretic action for better blood‑pressure control. - High blood pressure: improves overall vascular resistance and fluid balance.

Common Side Effects: - Dizziness: feeling light‑headed, especially after standing. - Headache: mild to moderate pain in the head region. - Fatigue: general tiredness or lack of energy. - Increased urination: more frequent bathroom visits due to diuretic action. - Electrolyte imbalance: mild reductions in potassium or sodium levels. - Mild gastrointestinal discomfort: occasional nausea or abdominal pain.

Serious or Rare Side Effects: - Severe dehydration: marked fluid loss requiring medical attention. - Acute kidney injury: sudden decline in renal function. - Hyperkalemia: dangerously high potassium levels. - Allergic reactions: rash, itching, swelling, or anaphylaxis. - Blood disorders: leukopenia, thrombocytopenia, or agranulocytosis. - Hepatic dysfunction: elevated liver enzymes or hepatitis.

Before initiating therapy, consider the following precautions: - Blood pressure monitoring: regularly check to ensure therapeutic targets are met. - Renal function assessment: evaluate serum creatinine and eGFR, especially in patients with pre‑existing kidney disease. - Electrolyte surveillance: monitor potassium and sodium levels during treatment. - Caution in elderly: dose adjustments may be needed due to altered pharmacokinetics. - Avoid in severe hepatic impairment: limited data support safe use. - Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Irbesartan/Hydrochlorothiazide may interact with several medicines. Review the following groups:

Major Interactions (Avoid): - Aliskiren: combined use can increase risk of renal dysfunction and hyperkalemia. - Potassium‑sparing diuretics: may cause dangerous elevations in serum potassium. - NSAIDs: can blunt antihypertensive effect and impair renal function. - Lithium: increased lithium levels leading to toxicity. - ACE inhibitors: additive risk of hyperkalemia and renal impairment.

Moderate Interactions (Monitor Closely): - Other thiazide diuretics: may enhance diuretic‑related electrolyte loss. - Antihypertensive agents: may require dose adjustment to avoid excessive hypotension. - Antidiabetic drugs: diuretic effect can alter glucose control. - Antidepressants (SSRIs): potential for increased hyponatremia. - Rifampin: may reduce plasma concentrations of irbesartan.